Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens in Patients with Gastro-Oesophageal Adenocarcinoma By Ogkologos - March 26, 2025 724 0 Facebook Twitter Google+ Pinterest WhatsApp Biomarker analyses from the CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not... April 8, 2025 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 A new target to slow down ageing and reduce blood cancer... June 29, 2023 What Are Patient-Reported Outcomes and Why Are They Important in Cancer... June 29, 2023 Load more HOT NEWS Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... Three Brothers Under The Age Of 6 Are All Fighting The... Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α New option to treat advanced oesophageal cancer approved for NHS in...
